Comparative Assessment of the Kinetics of Cellular and Humoral Immune Responses to COVID-19 Vaccination in Cancer Patients

Viruses, Journal Year: 2023, Volume and Issue: 15(7), P. 1439 - 1439

Published: June 26, 2023

Objective: The kinetics of immune responses to various SARS-CoV-2 vaccines in cancer patients were investigated. Methods: In total, 57 who received BNT162b2-RNA or BBIBP-CorV enrolled. Cellular and humoral immunity assessed at three-time points, before the first vaccine dose 14–21 days after second doses. Chemiluminescent microparticle immunoassay was used evaluate anti-spike IgG response, QuantiFERON® kit T-cell response. Results: Data showed that patients’ CD4+ CD8+ T cell-median IFN-γ secretion antigens increased doses (p = 0.027 p 0.042). BNT162b2 vaccinees had significantly higher levels cell epitopes than 0.028). There a positive correlation between antibody titer response regardless type < 0.05). Conclusions: This study is one investigate cellular immunization on active therapy each dose. COVID-19 immunizations helped develop an effective Understanding undergoing treatment necessary improve avoid future SARS pandemics.

Language: Английский

---

Assessment of the neutralizing antibody response in Omicron breakthrough cases in healthcare workers who received the homologous booster of Moderna mRNA-1273.

Virology, Journal Year: 2024, Volume and Issue: 595, P. 110082 - 110082

Published: April 8, 2024

Vaccines against SARS-CoV-2 were developed during the pandemic including BNT162b2 mRNA-1273. We evaluate levels of binding antibodies receptor domain and NAbs in individuals who a breakthrough infection after having received three doses A total 51 participants included. The group was compared to 1:1 matched-control group. Among individuals, 18 (35%) infection. GMT BA.1 BK population 278.1 (95%CI: 168.1–324.1). This titer significantly lower when considering all data (GMT = 477.4; 95%CI: 316.2–541.0; p 0.0057). Results similar for BA.5 152.0 76.9–172.9) 262.0 171.3–301.8) control (p 0.0043)). Our study found that receiving mRNA-1273 booster presented before as

Language: Английский

---

Hybrid adaptive immunity to SARS-CoV-2 protects against breakthrough infection after COVID-19 vaccination in ALSPAC participants.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: June 15, 2024

SUMMARY Immunological memory to vaccination and viral infection involves coordinated action of B T-cells, thus integrated analysis these two components is critical for understanding their contributions protection against breakthrough infections (BI). We investigated cellular humoral immune responses SARS-CoV-2 and/or COVID-19 in participants from the Avon Longitudinal Study Parents Children (ALSPAC). The magnitude antibody T-cell following second vaccine dose was associated with BI a history (cases), but not infection-naïve controls. Youden’s index thresholds were calculated all measures. Anti-Spike IgG (>666.4 BAU/mL) anti-Nucleocapsid pan Ig (>0.1332 combined 100% specific 83.3% sensitive cases without over 8-months follow-up. Collectively results point superior protective effect hybrid immunity have implications design next-generation vaccines.

Language: Английский

---

Modeling of anti-spike IgG and neutralizing antibody waning after anti-SARS-CoV-2 mRNA vaccination

Vaccine, Journal Year: 2024, Volume and Issue: 42(21), P. 126146 - 126146

Published: July 20, 2024

At present, mRNA-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being administered on a global scale. While the efficacy of mRNA has been demonstrated, several unknowns remains. For example, as number booster vaccinations increases, there uncertainties regarding how long effects vaccine will last and much individual variability exists. In this study, to predict duration efficacy, we modeled kinetics antibody levels for each SARS-CoV-2 vaccination dose, incorporating predictive intervals estimate account among individuals. A total 3,059 serum samples from 1,346 participants were assayed quantify IgG antibodies specific S1 subunit S protein (anti-S1 IgG) neutralizing activities SARS-CoV-2. power law model was used simulate decay titers following vaccination, models constructed assess level after second, third, fourth, fifth vaccinations. The assumed that would significantly reduce decline in anti-S levels, resulting maintained longer period. No significant differences rate observed age groups, yet peak higher ≤ 39 group than ≥ 60 second vaccination; these not third fourth modeling is considered be useful understanding immune status recipients.

Language: Английский

---

Delivery of SARS-CoV-2 spike and membrane genes in a single Baculoviral vector enhance the immune breadth against SARS-CoV-2 variants of concern

Vaccine, Journal Year: 2024, Volume and Issue: 42(26), P. 126355 - 126355

Published: Sept. 10, 2024

Language: Английский

---